Physician profile
Amanda K Lutter
NPI 1912322264
$2,926.80
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,669 · 2022: $1,258.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $341.03 | 2021-2022 | |
| United Therapeutics Corporation | $314.49 | 2021-2022 | |
| Pfizer INC. | $306.12 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $287.96 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $225.61 | 2021-2022 | |
| Alnylam Pharmaceuticals INC. | $207.41 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $201.71 | 2021-2022 | |
| Amgen INC. | $177.51 | 2021-2022 | |
| Edwards Lifesciences Corporation | $152.27 | 2021-2022 | |
| Esperion Therapeutics, INC. | $145.24 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $117.93 | 2021-2022 | |
| Actelion Pharmaceuticals US, INC. | $96.94 | 2021 | |
| Abbott Laboratories | $84.01 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $83.56 | 2021-2022 | |
| Amarin Pharma, INC. | $52.73 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $29.45 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $27.97 | 2021 | |
| Boston Scientific Corporation | $17.91 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $17.14 | 2022 | |
| Chiesi USA, INC. | $16.12 | 2022 | |
| Akcea Therapeutics, INC. | $12.55 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $11.14 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Lutter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.